As of January 1st, 2017, there came into effect new regulations of the Act of 6th September 2001, Law on Medicinal Products, introducing new obligations in the area of providing information on the medicinal products turnaround for the obliged entities, entrepreneurs in the area of pharmaceutical wholesale and general access drug stores, and the pharmacy departments in hospitals.
According to the regulations, the participants of the "distribution chain" are obliged to report the medicinal products turnaround data to the Integrated Monitoring System of Medicinal Products Turnaround (in Polish: Zintegrowany System Monitorowania Obrotu Produktami Leczniczymi, or: ZSMOPL)
The main goals of the Integrated Monitoring System of Medicinal Products Turnaround is support for the Public Administration Institutions, Main Pharmaceutical Inspectorate and the President of the Office for Registration of Medicinal Products and Biocidal Products, in their task of running the State's Medicinal Products Policy.
Integrated Monitoring System of Medicinal Products Turnaround will allow, among others, to monitor at the retail and wholesale level of the medicinal products Turnaround, and reporting this information to the proper institutions. The basic functionalities of this system will include gathering, processing and providing the data regarding turnaround of medicinal products, including:
Data regarding turnaround of the monitored products will be submitted on a daily basis. The whole range of information gathered within the system will allow for analysis of the wholesale and retail turnaround, quantities of the planned deliveries and about shortages of the medicinal products.